Sumitomo Mitsui Trust Holdings Inc. decreased its stake in Davita Inc (NYSE:DVA) by 6.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 468,199 shares of the company’s stock after selling 33,272 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned 0.29% of Davita worth $26,720,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Davita by 0.5% in the 2nd quarter. Vanguard Group Inc. now owns 13,652,940 shares of the company’s stock valued at $768,114,000 after buying an additional 64,415 shares in the last quarter. Par Capital Management Inc. boosted its holdings in shares of Davita by 40.6% in the 2nd quarter. Par Capital Management Inc. now owns 4,159,000 shares of the company’s stock valued at $233,985,000 after buying an additional 1,201,300 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Davita by 56.2% in the 2nd quarter. Invesco Ltd. now owns 3,662,685 shares of the company’s stock valued at $206,063,000 after buying an additional 1,317,725 shares in the last quarter. Viking Global Investors LP boosted its holdings in shares of Davita by 5.5% in the 2nd quarter. Viking Global Investors LP now owns 2,907,034 shares of the company’s stock valued at $163,550,000 after buying an additional 151,529 shares in the last quarter. Finally, Camber Capital Management LP boosted its holdings in shares of Davita by 33.3% in the 2nd quarter. Camber Capital Management LP now owns 2,000,000 shares of the company’s stock valued at $112,520,000 after buying an additional 500,000 shares in the last quarter. Institutional investors and hedge funds own 91.00% of the company’s stock.
DVA has been the subject of a number of recent research reports. William Blair cut shares of Davita from an “outperform” rating to a “market perform” rating in a research note on Wednesday, September 11th. TheStreet upgraded shares of Davita from a “c+” rating to a “b-” rating in a research note on Wednesday, July 24th. UBS Group decreased their price target on shares of Davita from $61.00 to $60.00 and set a “neutral” rating for the company in a research note on Thursday, August 22nd. SunTrust Banks increased their price target on shares of Davita to $72.00 and gave the stock a “hold” rating in a research note on Wednesday. Finally, Robert W. Baird cut shares of Davita from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $70.00 to $65.00 in a research note on Friday, July 26th. Nine equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Davita has a consensus rating of “Hold” and a consensus target price of $64.81.
Shares of NYSE:DVA opened at $69.85 on Friday. The stock has a market cap of $10.01 billion, a P/E ratio of 19.57, a P/E/G ratio of 0.62 and a beta of 1.59. The firm has a fifty day moving average price of $58.51 and a 200 day moving average price of $55.70. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.12 and a quick ratio of 1.10. Davita Inc has a 1-year low of $43.40 and a 1-year high of $70.51.
Davita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $1.53 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.24 by $0.29. The firm had revenue of $2.90 billion during the quarter, compared to analysts’ expectations of $2.85 billion. Davita had a net margin of 3.68% and a return on equity of 18.03%. Davita’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.56 EPS. Sell-side analysts expect that Davita Inc will post 5.19 EPS for the current fiscal year.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also: Penny Stocks, Risk and Reward Factors
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.